Meg Valeur-Jensen specializes in corporate partnering and licensing transactions along with a full range of clinical, regulatory, contracting and corporate services for emerging biotechnology companies. She received a B.A. in Biology in 1978 from Skidmore College, and a Ph.D. in Biochemistry and Molecular Biology in 1983 from Syracuse University. During the years 1983-1985, Meg was a Post-Doctoral Fellow at Harvard Medical School, in the Department of Genetics, as well as at Massachusetts General Hospital, in the Department of Molecular Biology.
Stanford University School of Law
Massachusetts General Hospital and
Harvard Medical School
Post-Doctoral Fellow 1983-85
Biochemistry and Molecular Biology
Meg was General Counsel for Retrophin, Inc. from 2014 to 2017. She was Executive Vice President and General Counsel of Neurocrine Biosciences, Inc. from 1999-2012 where she was responsible for all patent and corporate practice including management of patent portfolio and strategy, corporate partnering, regulatory compliance, public company issues and secretary to the Board of Directors and member of the Management Committee. Meg was Associate General Counsel Business Law Group of Amgen Inc. from 1991-1999, and was responsible for licensing and corporate partnering, mergers and acquisitions, clinical development, sales and marketing, regulatory affairs, and real estate. Prior to joining Amgen, Meg was an associate at Davis, Polk & Wardwell.
Meg is admitted to the state bars of Washington, New York, and California. She is a member of Life Science Washington (formerly Washington Biotechnology & Biomedical Association).